Indivior Share Price | |
---|---|
Price | 1,435.00 |
Bid | 1,454.00 |
Ask | 1,456.00 |
Change | -5.00 (-0.35%) |
Volume | 442,907 |
Open | 1,440.00 |
High | 1,474.00 |
Low | 1,435.00 |
Prev. Close | 1,440.00 |
Currency | GBX |
---|---|
Issue Country | GB |
Shares in Issue | 135.38m |
Market Capitalisation | £1.94b |
Market Size | 500 |
52 Week High | 1,927.00 |
52 Week High Date | 27-Jul-2023 |
52 Week Low | 1,128.00 |
52 Week Low Date | 19-Dec-2023 |
# Trades | 1,149 |
---|---|
Vol. Sold | 248,605 |
Sold Value | £3.45m |
Vol. Bought | 77,584 |
Bought Value | £1.10m |
PE Ratio | 1,827.03399 |
Earnings | 0.785426 |
Dividend | 0.00 |
Yield | 0.00% |
Date | Time | Trade Prc | Volume | Buy/Sell | Bid | Ask | Value | |
---|---|---|---|---|---|---|---|---|
03-May-24 | 00:00:00 | 1,440.00 | 43,623 | Unknown* | 1,454.00 | 1,456.00 | 628.17k | O Ordinary Delayed publication Was reported as OTC |
03-May-24 | 00:00:00 | 1,440.00 | 43,623 | Unknown* | 1,454.00 | 1,456.00 | 628.17k | O Ordinary Delayed publication Was reported as OTC |
03-May-24 | 16:49:22 | 1,435.00 | 256 | Sell* | 1,454.00 | 1,456.00 | 3,674 | O Ordinary |
03-May-24 | 16:47:01 | 1,451.648 | 7,000 | Buy* | 1,454.00 | 1,456.00 | 101.62k | O Ordinary |
03-May-24 | 16:35:08 | 1,435.00 | 161,823 | Sell* | 1,454.00 | 1,456.00 | 2m | UT Uncrossing Trade |
03-May-24 | 16:29:58 | 1,454.00 | 31 | Sell* | 1,454.00 | 1,456.00 | 450.74 | A Automatic Execution |
03-May-24 | 16:29:55 | 1,454.00 | 7 | Buy* | 1,452.00 | 1,454.00 | 101.78 | A Automatic Execution |
03-May-24 | 16:29:55 | 1,454.00 | 73 | Buy* | 1,452.00 | 1,454.00 | 1,061 | A Automatic Execution |
03-May-24 | 16:29:55 | 1,454.00 | 25 | Buy* | 1,452.00 | 1,454.00 | 363.50 | A Automatic Execution |
03-May-24 | 16:29:55 | 1,454.00 | 19 | Buy* | 1,452.00 | 1,454.00 | 276.26 | A Automatic Execution |
Announced | Traded | Action | Notifier | Price | Currency | Amount | Holding |
---|---|---|---|---|---|---|---|
18-Mar-24 | 15-Mar-24 | Transfer From | Ryan Preblick held the position of CFO & Executive Director at the time of this trade.Ryan Preblick | 0.00 | 3,920 | 229,089 | |
18-Mar-24 | 18-Mar-24 | Sell | Mark Crossley held the position of CEO at the time of this trade.Mark Crossley | 1,617.00 | GBX | 10,549 | 335,935 |
18-Mar-24 | 15-Mar-24 | Sell | Mark Crossley held the position of CEO at the time of this trade.Mark Crossley | 1,644.00 | GBX | 15,444 | 335,935 |
18-Mar-24 | 14-Mar-24 | Sell | Mark Crossley held the position of CEO at the time of this trade.Mark Crossley | 1,630.00 | GBX | 91,204 | 335,935 |
18-Mar-24 | 15-Mar-24 | Exercise of Option | Mark Crossley held the position of CEO at the time of this trade.Mark Crossley | 555.00 | GBX | 15,444 | 335,935 |
Indivior is working to change patients lives by developing medicines to treat addiction and serious mental illnesses.